Skip to main content
SpringerLink
Log in

Amyotrophe Lateralsklerose

Aktuelle klinische Studien und ihr pathogenetischer Hintergrund

Amyotrophic lateral sclerosis

Current clinical trials and underlying pathomechanisms

  • Übersichten
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Die amyotrophe Lateralsklerose (ALS) ist eine neurodegenerative Erkrankung, die innerhalb von 3–5 Jahren zum Tode führt. Die bisher einzige Substanz mit marginalem therapeutischem Potenzial ist der Glutamatantagonist Riluzol, der jedoch nur zu einer durchschnittlichen Lebensverlängerung von 3–4 Monaten führt. Daher hat die symptomatische Therapie einen hohen Stellenwert. In zahlreichen tierexperimentellen und klinischen Studien werden potenziell neuroprotektive Wirkstoffe für eine kausale Behandlung untersucht. In diesem Übersichtsartikel sollen im Kontext mit den zugrunde liegenden Wirkmechanismen aktuelle klinischen ALS-Studien vorgestellt werden.

Summary

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease leading to death after 3 to 5 years. The glutamate antagonist Riluzole currently is the only drug with marginal therapeutic benefit, but its effect on survival is modest, with an average increase of only 3–4 months. Therefore symptomatic treatment still is the most important. Further neuroprotective agents are currently under investigation, both in transgenic animal models of ALS and clinical trials in ALS patients. This review summarizes the current state of clinical studies in ALS patients in the context of underlying therapeutic mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Almer G, Guegan C, Teismann P et al. (2001) Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 49: 176–185

    Article  PubMed  CAS  Google Scholar 

  2. Almer G, Teismann P, Stevic Z et al. (2002) Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 58: 1277–1279

    PubMed  CAS  Google Scholar 

  3. Angelov DN, Waibel S, Guntinas-Lichius O et al. (2003) Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 100: 4790–4795

    Article  PubMed  CAS  Google Scholar 

  4. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357–366

    Article  PubMed  CAS  Google Scholar 

  5. Beal MF, Ferrante RJ, Browne SE et al. (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42: 644–654

    Article  PubMed  CAS  Google Scholar 

  6. Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585–591

    Article  PubMed  CAS  Google Scholar 

  7. Borasio GD, Robberecht W, Leigh PN et al. (1998) A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51: 583–586

    PubMed  CAS  Google Scholar 

  8. Bowling AC, Schulz JB, Brown RH Jr, Beal MF (1993) Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 61: 2322–2325

    Article  PubMed  CAS  Google Scholar 

  9. Brooks B, Sanjak M, Roelke K et al. (2005) Phase 2B randomized dose-ranging clinical trial of tamoxifen, a selective estrogen receptor modulator (SERM), in ALS: sensitivity analyses of discordance between survival and fucitonal outcomes with long-term follow-up. Amyotroph Lateral Scler Other Motor Neuron Disord [Suppl 1] 6: 118

  10. Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 723–749

    Article  PubMed  CAS  Google Scholar 

  11. Carri MT, Grignaschi G, Bendotti C (2006) Targets in ALS: designing multidrug therapies. Trends Pharmacol Sci 27: 267–273

    Article  PubMed  CAS  Google Scholar 

  12. Chou SM, Wang HS, Taniguchi A, Bucala R (1998) Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Medicine 4: 324–332

    CAS  Google Scholar 

  13. Clement AM, Nguyen MD, Roberts EA et al. (2003) Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302: 113–117

    Article  PubMed  CAS  Google Scholar 

  14. Crow JP, Calingasan NY, Chen J et al. (2005) Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 58: 258–265

    Article  PubMed  CAS  Google Scholar 

  15. Cudkowicz M, Shefner, J, Simpson E et al. (2006) A multicenter, dose ranging safety and pharmacokinetics study of arimoclomol in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 7: 113

    Google Scholar 

  16. Danzeisen R, Schwalenstoecker B, Gillardon F et al. (2006) Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 316: 189–199

    Article  PubMed  CAS  Google Scholar 

  17. Di Giorgio FP, Carrasco MA, Siao MC et al. (2007) Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 10: 608–614

    Article  CAS  Google Scholar 

  18. Do TQ, Schultz JR, Clarke CF (1996) Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids. Proc Natl Acad Sci U S A 93: 7534–7539

    Article  PubMed  CAS  Google Scholar 

  19. Dobrowolny G, Giacinti C, Pelosi L et al. (2005) Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 168: 193–199

    Article  PubMed  CAS  Google Scholar 

  20. Drachman DB, Frank K, Dykes-Hoberg M et al. (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52: 771–778

    Article  PubMed  CAS  Google Scholar 

  21. Ferrante KL, Shefner J, Zhang H et al. (2005) Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65: 1834–1836

    Article  PubMed  CAS  Google Scholar 

  22. Ferrante RJ, Browne SE, Shinobu LA et al. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69: 2064–2074

    Article  PubMed  CAS  Google Scholar 

  23. Ferrante RJ, Shinobu LA, Schulz JB et al. (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 42: 326–334

    Article  PubMed  CAS  Google Scholar 

  24. Gordon PH, Moore DH, Gelinas DF et al. (2004) Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62: 1845–1847

    PubMed  CAS  Google Scholar 

  25. Greig NH, Mattson MP, Perry T et al. (2004) New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 1035: 290–315

    Article  PubMed  CAS  Google Scholar 

  26. Guegan C, Vila M, Rosoklija G et al. (2001) Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 21: 6569–6576

    PubMed  CAS  Google Scholar 

  27. Guglielmo BJ, Luber AD, Paletta D Jr, Jacobs RA (2000) Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis 30: 205–207

    Article  PubMed  CAS  Google Scholar 

  28. Gurney ME, Cutting FB, Zhai P et al. (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39: 147–157

    Article  PubMed  CAS  Google Scholar 

  29. Hargitai J, Lewis H, Boros I et al. (2003) Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 307: 689–695

    Article  PubMed  CAS  Google Scholar 

  30. Haverkamp LJ, Smith RG, Appel SH (1994) Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 36: 253–254

    Article  PubMed  CAS  Google Scholar 

  31. Henkel JS, Engelhardt JI, Siklos L et al. (2004) Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 55: 221–235

    Article  PubMed  CAS  Google Scholar 

  32. Hensley K, Fedynyshyn J, Ferrell S et al. (2003) Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 14: 74–80

    Article  PubMed  CAS  Google Scholar 

  33. Hensley K, Floyd RA, Gordon B et al. (2002) Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 82: 365–374

    Article  PubMed  CAS  Google Scholar 

  34. Hu JH, Zhang H, Wagey R et al. (2003) Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J Neurochem 85: 432–442

    Article  PubMed  CAS  Google Scholar 

  35. Kaspar BK, Llado J, Sherkat N et al. (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839–842

    Article  PubMed  CAS  Google Scholar 

  36. Katsumata S, Tateishi N, Kagamiishi Y et al. (1999) Inhibitory effect of ONO-2506 on GABAA receptor disappearance in cultered astrocytes and ischemic brain. Soc Neurosci 11: 843 (Abstr)

    Google Scholar 

  37. Kiaei M, Kipiani K, Petri S et al. (2005) Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegen Dis 2: 246–254

    Article  CAS  Google Scholar 

  38. Kiaei M, Petri S, Kipiani K et al. (2006) Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 26: 2467–2473

    Article  PubMed  CAS  Google Scholar 

  39. Kieran D, Kalmar B, Dick JR et al. (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10: 402–405

    Article  PubMed  CAS  Google Scholar 

  40. Klivenyi P, Kiaei M, Gardian G et al. (2004) Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 88: 576–582

    Article  PubMed  CAS  Google Scholar 

  41. Kornhuber J, Quack G (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195: 137–139

    Article  PubMed  CAS  Google Scholar 

  42. Kriz J, Nguyen MD, Julien JP (2002) Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10: 268–278

    Article  PubMed  CAS  Google Scholar 

  43. Lacomblez L, Bensimon G, Leigh PN et al. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347: 1425–1431

    PubMed  CAS  Google Scholar 

  44. Lai EC, Felice KJ, Festoff BW et al. (1997) Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49: 1621–1630

    PubMed  CAS  Google Scholar 

  45. Lambrechts D, Lafuste P, Carmeliet P, Conway EM (2006) Another angiogenic gene linked to amyotrophic lateral sclerosis. Trends Mol Med 12: 345–347

    Article  PubMed  CAS  Google Scholar 

  46. Mackenzie IR, Bigio EH, Ince PG et al. (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61: 427–434

    Article  PubMed  CAS  Google Scholar 

  47. Matthews RT, Yang L, Browne S et al. (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A 95: 8892–8897

    Article  PubMed  CAS  Google Scholar 

  48. Mercuri E, Bertini E, Messina S et al. (2004) Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 14: 130–135

    Article  PubMed  Google Scholar 

  49. Meyer T MA, Borisow N, Dullinger J et al. (2007) Thalidomide causes sinus bradycardia in ALS. Akt Neurol 34: 69

    Google Scholar 

  50. Nagai M, Re DB, Nagata T et al. (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10: 615–622

    Article  PubMed  CAS  Google Scholar 

  51. Neumann M, Sampathu DM, Kwong LK et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130–133

    Article  PubMed  CAS  Google Scholar 

  52. Nilsson M, Hansson E, Ronnback L (1992) Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures. Neurochem Res 17: 327–332

    Article  PubMed  CAS  Google Scholar 

  53. Oteiza PI, Uchitel OD, Carrasquedo F et al. (1997) Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res 22: 535–539

    Article  PubMed  CAS  Google Scholar 

  54. Pasinelli P, Houseweart MK, Brown RH Jr, Cleveland DW (2000) Caspase-1 and −3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 97: 13901–13906

    Article  PubMed  CAS  Google Scholar 

  55. Patel M, Day BJ (1999) Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol Sci 20: 359–364

    Article  PubMed  CAS  Google Scholar 

  56. Petri S, Kiaei M, Kipiani K et al. (2006) Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22: 40–49

    Article  PubMed  CAS  Google Scholar 

  57. Rosen DR, Siddique T, Patterson D et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62

    Article  PubMed  CAS  Google Scholar 

  58. Rothstein JD, Van Kammen M, Levey AI et al. (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38: 73–84

    Article  PubMed  CAS  Google Scholar 

  59. Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Engl J Med 344: 1688–1700

    Article  PubMed  CAS  Google Scholar 

  60. Ryu H, Smith K, Camelo SI et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93: 1087–1098

    Article  PubMed  CAS  Google Scholar 

  61. Sekizawa T, Openshaw H, Ohbo K et al. (1998) Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 154: 194–199

    Article  PubMed  CAS  Google Scholar 

  62. Shefner JM, Cudkowicz ME, Schoenfeld D et al. (2004) A clinical trial of creatine in ALS. Neurology 63: 1656–1661

    PubMed  CAS  Google Scholar 

  63. Shibata N, Nagai R, Uchida K et al. (2001) Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917: 97–104

    Article  PubMed  CAS  Google Scholar 

  64. Siklos L, Engelhardt J, Harati Y et al. (1996) Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 39: 203–216

    Article  PubMed  CAS  Google Scholar 

  65. Smith RG, Henry YK, Mattson MP, Appel SH (1998) Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 44: 696–699

    Article  PubMed  CAS  Google Scholar 

  66. Storkebaum E, Lambrechts D, Dewerchin M et al. (2005) Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8: 85–92

    Article  PubMed  CAS  Google Scholar 

  67. Strong M, Rosenfeld J (2003) Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 4: 136–143

    Article  PubMed  Google Scholar 

  68. Strong MJ, Kesavapany S, Pant HC (2005) The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol 64: 649–664

    Article  PubMed  CAS  Google Scholar 

  69. Sugai F, Yamamoto Y, Miyaguchi K et al. (2004) Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 20: 3179–3183

    Article  PubMed  Google Scholar 

  70. Tan CF, Eguchi H, Tagawa A et al. (2007) TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol (Berl) 113: 535–542

    Google Scholar 

  71. Traynor BJ, Bruijn L, Conwit R et al. (2006) Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67: 20–27

    Article  PubMed  CAS  Google Scholar 

  72. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W (2002) Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13: 1067–1070

    Article  Google Scholar 

  73. Van Muiswinkel FL, Kuiperij HB (2005) The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets 4: 267–281

    Article  Google Scholar 

  74. Wang R, Zhang D (2005) Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci 22: 2376–2380

    Article  PubMed  Google Scholar 

  75. Wilms H, Sievers J, Dengler R et al. (2003) Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol 144: 139–142

    Article  PubMed  CAS  Google Scholar 

  76. Wu AS, Kiaei M, Aguirre N et al. (2003) Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 85: 142–150

    Article  PubMed  CAS  Google Scholar 

  77. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease–a double-edged sword. Neuron 35: 419–432

    Article  PubMed  CAS  Google Scholar 

  78. Yim MB, Kang JH, Yim HS et al. (1996) A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci U S A 93: 5709–5714

    Article  PubMed  CAS  Google Scholar 

  79. Yoshihara T, Ishigaki S, Yamamoto M et al. (2002) Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 80: 158–167

    Article  PubMed  CAS  Google Scholar 

  80. Zhang W, Narayanan M, Friedlander RM (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53: 267–270

    Article  PubMed  CAS  Google Scholar 

  81. Zhu S, Stavrovskaya IG, Drozda M et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74–78

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover, Deutschland

    K. Kollewe, R. Dengler & S. Petri

Authors
  1. K. Kollewe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Dengler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Petri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Kollewe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kollewe, K., Dengler, R. & Petri, S. Amyotrophe Lateralsklerose. Nervenarzt 79, 653–661 (2008). https://doi.org/10.1007/s00115-007-2403-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-007-2403-0

Schlüsselwörter

Keywords

Search

Navigation